FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate
[5-XX-2016] The U.S. Food and Drug Administration (FDA) is alerting the public about interim safety results from an ongoing clinical trial that found an increase in leg and foot amputations, mostly affecting the toes, in patients treated with the diabetes medicine canagliflozin (Invokana, Invokamet). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 9, 2017 Category: Drugs & Pharmacology Source Type: news
Real-World Evidence Shows Oral INVOKANA ® 300 mg Demonstrates Comparable A1C Reduction and Control to Injectable GLP-1 Receptor Agonists
Patients Taking INVOKANA ® 300 mg Were Significantly Less Likely to Discontinue the Medication or Be Prescribed a New Antihyperglycemic Agent (Source: Johnson and Johnson)
Source: Johnson and Johnson - May 6, 2017 Category: Pharmaceuticals Source Type: news
Invokamet (Canagliflozin and Metformin Hydrochloride Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 17, 2017 Category: Drugs & Pharmacology Source Type: news
Invokamet XR (canagliflozin and metformin hydrochloride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 17, 2017 Category: Drugs & Pharmacology Source Type: news
Invokana (Canagliflozin Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 17, 2017 Category: Drugs & Pharmacology Source Type: news
EMA: Amputation Warning With SGLT2 Inhibitors Must Be on Label EMA: Amputation Warning With SGLT2 Inhibitors Must Be on Label
Lower-limb (mostly toe) amputation risk seen in canagliflozin clinical trials, but EMA panel says all SGLT2 inhibitors should carry the label warning.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 10, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Randomized trial will reveal diabetes drug's effects on kidney health
(Wiley) Type 2 diabetes often causes damaging effects to the kidneys, sometimes resulting in the need for dialysis or kidney transplantation. The ongoing CANVAS-R trial is testing whether canagliflozin -- a member of a new class of diabetes treatments known as sodium glucose co-transporter 2 (SGLT2) inhibitors -- can slow kidney function decline and provide other benefits to diabetic patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 25, 2017 Category: Global & Universal Source Type: news
The Year In Review: Merck Can Look Back And Smile
Merck has had a reasonably good year. The company saw a turn-around in its business on the back of its relatively new cancer drug, Keytruda. The anti-infectives division sustained itself, with key metabolism drugs Januvia and Janumet gradually inching up. In fact, the competitive pressure from J&J ’s Invokana, which threatened [...] (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 13, 2016 Category: Pharmaceuticals Authors: Trefis Team, Contributor Tags: NYSE:MRK Source Type: news
Money in Medicine: The top 30 drugs associated with pharma industry payments to Oregon doctors
The top 30 drugs associated with pharmaceutical industry payments to doctors are, for the most part, not household names.
The top three — Bydureon, Invokana and Toujeo — are prescribed for diabetes, testament to the prevalence of the disease. Three others on the list are prescribed for multiple sclerosis. Hysingla, a an abuse-deterrent hydrocodone pill, is also high on the list.
The makers of these drugs pay doc tors in Oregon and across the nation billions of dollars for consulting fees, talks… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 21, 2016 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news
Money in Medicine: The top 30 drugs associated with pharma industry payments to Oregon doctors
The top 30 drugs associated with pharmaceutical industry payments to doctors are, for the most part, not household names.
The top three — Bydureon, Invokana and Toujeo — are prescribed for diabetes, testament to the prevalence of the disease. Three others on the list are prescribed for multiple sclerosis. Hysingla, a an abuse-deterrent hydrocodone pill, is also high on the list.
The makers of these drugs pay doc tors in Oregon and across the nation billions of dollars for consulting fees, talks… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 21, 2016 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news
Invokamet XR for the Treatment of Type 2 Diabetes in Adults
Developed by Janssen Pharmaceuticals, Invokamet XR (Canagliflozin / Metformin Hydrochloride Extended Release) is indicated for the treatment of Type 2 diabetes in adults. (Source: Drug Development Technology)
Source: Drug Development Technology - November 17, 2016 Category: Pharmaceuticals Source Type: news
Invokamet XR (canagliflozin and metformin hydrochloride) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 30, 2016 Category: Drugs & Pharmacology Source Type: news
U.S. FDA Approves INVOKAMET(R) XR (Canagliflozin / Metformin Hydrochloride Extended-Release) for the Treatment of Adults with Type 2 Diabetes
RARITAN, N.J., Sept. 21, 2016 -- (Healthcare Sales & Marketing Network) -- Janssen Pharmaceuticals, Inc. (Janssen) announced today the U.S. Food and Drug Administration (FDA) has approved INVOKAMET® XRa once-daily, fixed-dose combination therapy of c... Biopharmaceuticals, Endocrinology, FDA Janssen, INVOKAMET, Canagliflozin, Metformin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 21, 2016 Category: Pharmaceuticals Source Type: news
FDA Approves Invokamet XR (Canagliflozin/Metformin Hydrochloride Extended-Release) for the Treatment of Adults with Type 2 Diabetes
RARITAN, N.J., September 21, 2016 – Janssen Pharmaceuticals, Inc. (Janssen) announced today the U.S. Food and Drug Administration (FDA) has approved Invokamet XR - a once-daily, fixed-dose combination therapy of canagliflozin and metformin... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 21, 2016 Category: Drugs & Pharmacology Source Type: news
3 Simple Ways to Manage Diabetes
Image Source
With as much as three million Americans living with type 1 diabetes (T1B), and an alarming 371 million of the world's population living with the disease, finding an effective and yet simple way to manage it is a step anyone with diabetes should look to.
With no current cure, diabetes easily falls among one of the world's scariest diseases. Experts have recommended maintaining a healthy living and eating habit as a way to manage the disease and/or prevent it for those who are yet to be diagnosed with it.
For people who have been diagnosed with diabetes, worrying and allowing the ailment to get the better part...
Source: Healthy Living - The Huffington Post - September 2, 2016 Category: Consumer Health News Source Type: news
